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Introduction: Due to increasing use of disease modifying antirheumatic drugs (DMARDs) as first line therapy in
rheumatic diseases, dental and maxillofacial practitioner should be aware of drug related adverse events. Especially
effects on bone-metabolism and its cells are discussed controversially. Therefore we investigate the in vitro effect of
short time administration of low dose methotrexate (MTX) on osteoblasts as essential part of bone remodelling
cells.
Methods: Primary bovine osteoblasts (OBs) were incubated with various concentrations of MTX, related to tissue
concentrations, over a period of fourteen days by using a previously established standard protocol. The effect on
cell proliferation as well as mitochondrial activity was assessed by using 3-(4, 5-dimethylthiazol-2-yl) 2,
5-diphenyltetrazolium bromide (MTT) assay, imaging and counting of living cells. Additionally, immunostaining of
extracellular matrix proteins was used to survey osteogenic differentiation.
Results: All methods indicate a strong inhibition of osteoblast`s proliferation by short time administration of low
dose MTX within therapeutically relevant concentrations of 1 to 1000nM, without affecting cell differentiation of
middle-stage differentiated OBs in general. More over a significant decrease of cell numbers and mitochondrial
activity was found at these MTX concentrations. The most sensitive method seems to be the MTT-assay.
MTX-concentration of 0,01nM and concentrations below had no inhibitory effects anymore.
Conclusion: Even low dose methotrexate acts as a potent inhibitor of osteoblast’s proliferation and mitochondrial
metabolism in vitro, without affecting main differentiation of pre-differentiated osteoblasts. These results suggest
possible negative effects of DMARDs concerning bone healing and for example osseointegration of dental implants.
Especially the specifics of the jaw bone with its high vascularisation and physiological high tissue metabolism,
suggests possible negative effects of DMARD therapy concerning oral and cranio-maxillofacial bone surgery as
could be seen in a similar way in bisphosphonate related osteonecrosis of the jaw.
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Rheumatoid arthritis (RA) is a chronic autoimmune disease,
clinically characterized by chronic synovitis, serological ab-
normalities, acute-phase reactants, and symptoms like pain
or stiffness, leading to a score≥6 of 10 as established by the
2010 classification criteria of the American college of
rheumatology and European league against rheumatism [1].* Correspondence: tobias.annussek@ukmuenster.de
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of newer molecular and cellular understanding of RA the
pathophysiological pathways and etiology of disease is not
already understood in detail [3]. Impact of RA seems to be
highly associated with genetic susceptibility, environmental
factors and changes in mesenchymal tissue. As genetic fac-
tors association with human leukocyte antigen-DRB1 allels,
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fragment of human IgG [4]. Most dominant environmental
factors are smoking, age and gender (male / female ratio
1/3) [5]. Local Tissue consists of four major types of
cells involved in rheumatoid synovial inflammation, the
fibroblast-like cells, macrophage like cells as well lympho-
cytes (T and B Cells). Most insights indicate that RA starts
in the joints with enhanced cytokine production by
macrophage- and fibroblast-like synoviocytes. These cyto-
kines activate pathways of the adaptive immune system es-
pecially targeting T-cell subsets and regulatory T-cells,
leading to macrophages, chondrocytes and osteoclasts
driven tissue damage [6]. However, the increasing age of
patients is highly associated with the contract of RA and
edentulism. Moreover, the growing evidence suggests an as-
sociation between periodontal disease and systemic diseases
such as rheumatoid arthritis [7]. Therefore, patients suffer-
ing from RA, show characteristics that confirm to lots of
patients daily locating our hospital. Since the paradigm shift
in RA therapy no longer the reduction of symptoms by the
use of analgetics or anti-inflammatory drugs (NSAIDs) is
the overarching principle. Actually treatment of disease is
dominated by an aggressive and early use of disease modify-
ing anti-rheumatic drugs as recommended by the ACR and
EULAR [8]. Therefore, the availability of new therapies in
rheumatoid arthritis, especially the admission of newer anti-
rheumatic drugs increases remarkably during the last dec-
ades [9]. DMARDs are a heterogeneous group of agents,
whose diverse mechanisms of action are not already
understood. The most often and usually first time adminis-
tered DMARD is methotrexate. MTX was primary used at
high dosages (100-1000mg) in oncology as anti-neoplastic
agent. First data of low dose MTX use in RA Therapy go
back to the 1960s. In the following years doses ranged from
2,5-25 mg once weekly, administered orally, intravenously
or even subcutaneously [10]. Actually it is still the anchor
drug in RA Therapy, with mean dosage of 7,5 mg once
weekly, whereas latest reports of the ACR and EULAR rec-
ommend higher dosages. However, the precise understand-
ing of antirheumatic action in spite of antineoplastic action
remains uncertain. It is known that high concentrations of
MTX as a folic acid antagonist, inhibits the de novo purine
and pyrimidine synthesis. Intracellular, a part of MTX
undergoes polyglutamination (MTXglu). Both, MTX and
MTXglu inhibit the dihydrofolate reductase (DHFR), thy-
midylat synthase and 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR) transformylase, which leads to ac-
cumulation of extracellular adenosine by devious inhibition
of AMP deaminase and primary derived from adenine
nucleotides. This extracellular adenosine accumulation has
been found out to mediate the anti-inflammatory effect of
MTX [11-13]. Adverse reactions of MTX are well documen-
ted in literature, even if it is often described as generally well
tolerated and to possess a superior safety profile [14,15]. Infact, side effects of DMARDs are discussed controversially.
It is already recognized that high dose MTX therapy causes
osteoporosis in predisposed patients [16]. Just rare data exist
concerning metabolic changes impairing osteogenic path-
ways affected by low dose MTX therapy. However, one of
the most important tissues, which is routinely affected by
maxillofacial surgery in the context of fractures, orthog-
nathic surgery, implantology or temporo-mandibular joint
diseases is the jaw bone and therefore bone metabolism with
its bone forming osteoblasts. This emphasizes the demand
of a detailed knowledge of disease specific metabolic
changes and pathogenesis, as well as potential side effects
and adverse events of disease modifying antirheumatic
drugs affecting cranio-maxillofacial surgery. Especially
neurological, phylogenetic and metabolic specifics of the
cranio-maxillofacial region amplify this request.
Therefore we investigate the proliferation, mitochondrial
metabolism and differentiation of primary bovine osteoblasts
on clinically relevant concentrations of MTX, to determine
potential side effects and risks of low dose methotrexate on
the osseous structures of the oral cavity and facial region.
Materials and methods
Cell culture
Osteoblasts were cultured from the periosteal layer of
calf metacarpals according to the method of Jones et al.
[17]. In detail, 4x3mm pieces of periosteal layer where
seeded into culture dishes of 136 mm diameter (TPP
AG, Trasadingen, Switzerland) with the osteogenic layer
facing downwards to afford the osteoprogenitor cells to
migrate from the tissue explants. After one week, the
pieces were removed and primary cells were cultured for
three more weeks by using High Growth Enhancement
Medium (MP Biomedicals, Eschwege, Germany), sup-
plemented with 10% foetal calf serum (Biochrom KG,
Berlin, Germany), 10.000 IU/ml penicillin, 10.000 μg/ml
streptomycin and 250 μg/ml amphotericin (Biochrom
KG, Berlin, Germany) at 37°C and 5% C02 in humidified
air. When primary osteoblasts reached confluence they
were washed three times with phosphate-buffered-saline
and harvested by ten minutes of incubation with accu-
tase (PAA Laboratories, Cölbe, Germany). Afterwards,
cells were pelleted by centrifugation. Cell number and
size were determined using an electric field multi-channel
cell counting system (CASY I, Schärfe System, Reutlingen,
Germany). The resuspended cells were seeded into 24
well-plates (TPP AG, Trasadingen, Switzerland) at concen-
trations of 1x104 cells per well and incubated for two more
weeks with a solution of culture medium supplemented
with MTX concentrations from 1 to 1000nM, according to
MTX concentrations found in cortical bone of RA patients
[18]. Additionally cells were cultured under same con-
ditions on culture dishes of 87.2 mm diameter (NUNC,
Langenselbold, Germany). Control samples, cultured in
Figure 1 a. Richardson – staining at Control without MTX (day 7, 10x). b. Richardson – staining at 1000 nM MTX (day 7, 10x).
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gation. An exponential dilution series of cells with 1 × 106
cells per well as a starting point, were used to check meth-
odology and to ensure that cells used for experiments were
in the exponential growth phase. Since the beginning of the
experimental procedure cell morphology was monitored
daily by phase-contrast light microscopy. All samples were
done independently in double triplicates (total n=516).
Medium was changed twice weekly.
Cell Counting
After day 1, 3, 6, 10 and 14 post MTX addition cell pro-
liferation was measured by standardised taking digitalphoto (NIS Elements 2.20, Nikon Instruments Inc.,
Melville, NY, USA) of each well and counting of living
cells per unit area using Java-based image processing
program (Image J Cell Counter, National Institute of
Health, USA). The procedure was performed by two
different and blinded examiners (n = 300).
MTT-assay
To determine cell viability and mitochondrial activity we
performed a 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl-
tetrazolium bromide (MTT) assay (SigmaAldrich Co.,
St. Louis, MO, USA). At the same days, when digital
photos were taken, cells were incubated for one hour
Figure 2 a. Osteocalcin – immunostaining at Control without MTX
(day 7, 10x). b. Osteocalcin – immunostaining at 1000 nM MTX
(day 7, 10x).
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time, medium was aspirated and 200 μl of propanol was
added to lyse the cells and dissolve the released forma-
zan crystals (n = 150). The extinction was measured at a
wavelength of 570 nm using an enzyme-linked immuno-
sorbent assay reader (μQuant, Biotek instruments, Bad
Friedrichshall, Germany).Immunostaining
The additional culture dishes were used to characterize
osteoblasts by immunostaining. When control samples
reached confluence, the expression of collagen I, osteo-
calcin and osteonectin was determined. Therefore cells
were washed two times with phosphate buffered saline
and fixated for 20 minutes at −20°C. Blocking solution
(CANDOR Bioscience, Wangen, Germany) was used for
15 minutes, before 60 minutes of incubation with pri-
mary antibodies (collagen I 488 rabbit, Biotrend, Köln,
Germany; osteocalcin 488 mouse and osteonectin
488 mouse, TaKaRa, Saint-Germain-en-Laye, France).Secondary antibodies (Biochrom K4000, 4002, Biochrom
KG, Berlin, Germany) were used according to the manu-
facture`s instruction (n = 30).
Critical concentration identification
After first analysis of data of cell counting and MTT –
assay, we saw an inhibitory effect of MTX on osteoblasts
for all administered concentrations from 1 to 1000 nM
compared to control without MTX, as described below
in the results chapter in detail. Due to this fact, further
experiments were performed to evaluate the critical
value of that MTX-concentration, in which no more in-
hibition of proliferation or mitochondrial activity could
be assessed. Osteoblasts were seeded into 24 well-plates
(TPP AG, Trasadingen, Switzerland) at concentrations of
1x104 cells per well as described before and incubated
for one week with a solution of culture medium supple-
mented with MTX concentrations from 0,0001 to 1 nM
(n= 36).
Statistical analysis
The effect of MTX on proliferation and viability, re-
spectively mitochondrial metabolism of osteoblasts were
evaluated by using analysis of variance (ANOVA, post
hoc Tamhane T2 – test) to distinguish between groups
of different MTX-concentrations. Interrater reliability
between the two examiners was tested calculating
Cohen´s kappa. All statistical analyses were performed
using SPSS software (version 15.0; SPSS Inc., Chicago,
Illinois, USA).
Results
Cell morphology and immunostaining
At the beginning of experimental procedure cell morph-
ology was measured by daily phase contrast microscopy
and adjudged as unaltered. The cultured cells showed
typical characteristics of osteoblasts without any identifi-
able changings. Cells were displayed with flattened, spin-
dle shaped bodies and bipolar processes. At starting
point, mean diameter of OBs was 16,72 μm , assessed by
electronic particle counter (CASY I TT, Schärfe System
GmbH, Reutlingen, Germany). 72 h after incubation
with MTX concentrations from 1-1000nM first changes
could be observed in cultures, substituted with 100nM
and 1000nM. Osteoblasts of the MTX group in contrast
to the control group without MTX-addition, were less
proliferating, as seen by the bright gaps between the
cells, and developing longer cell-processes to get in con-
tact with each other (Figure 1a, 1b). At day 6 these dif-
ferences appeared at all MTX concentrations without
noticeable discrepancy within MTX groups. Moreover,
till day 14, cells which were incubated with different
MTX concentrations, developed more voluminous cell
bodies.
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collagen I, osteonectin, and osteocalcin, was not altered in
general by addition of MTX (Figures 2a, 2b, 3a, 3b). At all
samples bone specific proteins were detectable till the end
of experimental procedure, even if the quantitatively
observed expression seems to be decreased.Cell counting
After 24 h of incubation, number of cells attached on the
polystyrene surfaces per unit area, were relatively con-
stant between MTX and control groups. With p-values
≥ 0.085 no statistical significance was observed neither
between MTX concentrations nor to control group. At
day 3 we firstly found significant decrease in cell number
concerning wells incubated with 1nM (p= 0.03) and
1000nM (p = 0.042) (Table 1). Moreover, no significant
changes in cell number within the MTX concentrations
from 1-1000nM could be observed. After six days of
MTX incubation highly significant differences were
found between all MTX concentrations compared toFigure 3 a. Collagen I – immunostaining at Control without
MTX (day 7, 10x). b. Collagen I – immunostaining at 1000 nM MTX
(day 7, 10x).control (p≤ 0.001). This inhibitory effect of MTX was
seen also at day 10 at the same level of high significance
and lasted until day 14, when differences to control
group in cell numbers per unit reached a maximum
(Figure 4). In addition, significant differences in cell
numbers occurred between MTX concentrations of 1nM
and 1000nM (p = 0.041). For all measurements, interexa-
miner reliability was high with Cohen´s kappa κ= 0.937.
MTT-assay
The first assay was performed 24h after methotrexate ad-
ministration to ensure that osteoblasts were attached to
polystyrene well surfaces as proven before. In spite of
MTX groups, within no statistical significant differences
in extinction values were found, all MTX concentrations
showed significant lower extinction and therefore decrease
of detectable mitochondrial activity compared to cells
without MTX addition. Within MTX concentrations of
1nM - 10nM as well as 1000nM p-value was between
0.012 and 0.039. Concerning MTX concentration of
100nM, highly significant reduction of cell viability could
be observed during the first day of incubation. From the
beginning of day 3, extinction values started to differ
within MTX groups but without straight proportionality
to concentration. Reduction of mitochondrial activity was
however highly significant to control (p≤ 0.001). Till day
10 varying decrease of viability was measured and stayed
at high level of significance. Then differences between
extinction of the MTX groups themselves started to be-
came significant (Table 2, Figure 5). Between 1nM/10nM,
10/100nM and 1-1000nM/0nM p-value was between
0.007 and≤ 0.001. The maximum of reduction was found
at day 14 between 10nM and control, with a mean differ-
ence of 0.439 of extinction. In comparison of cell number
and mitochondrial activity (MTT-assay), the average
extinction per cell decreases statistically significant within
MTX groups.
Detection of critical MTX-concentration
MTX-concentrations of 1nM and 0.1nM showed still
statistical significant inhibition of osteoblast`s prolifera-
tion and viability. Concentrations equal to or lower than
0.01nM MTX showed no inhibitory effects concerning
cell proliferation, determined by cell counting, and mito-
chondrial metabolism, measured using the MTT-assay.
From the beginning of day 7, differences between vari-
ous MTX levels reached highest levels of statistical sig-
nificance (Table 3). Between concentrations of 0.0001nM
to 0.01nM no differences between MTX groups them-
selves neither to control group (no MTX, i.e. 0nM)
could be found. Administration of 0.1nM MTX lead to
highly significant reduction of measured MTT-absorption
(p≤ 0.001) compared to control and concentrations of
0.0001-0.01nM MTX. Mitochondrial activity, as measured
Table 2 Results of measurement of MTT – assay
extinction values
MTX – concentration
Control 1 nM 10 nM 100 nM 1000 nM
Day 1 mean 0.101 0.087 0.089 0.081 0.085
SD 0.009 0.013 0.011 0.009 0.013
Day 3 mean 0.163 0.117 0.104 0.110 0.111
SD 0.018 0.012 0.005 0.007 0.005
Day 6 mean 0.603 0.218 0.226 0.234 0.224
SD 0.051 0.009 0.010 0.012 0.018
Day 10 mean 0.752 0.341 0.313 0.329 0.356
SD 0.031 0.015 0.012 0.005 0.040
Day 14 mean 0.852 0.448 0.411 0.432 0.404
SD 0.102 0.019 0.008 0.021 0.037
Table 1 Results of Cell Counting
MTX – concentration
Control 1 nM 10 nM 100 nM 1000 nM
Day 1 mean 13.08 11.76 17.52 16.67 13.31
SD 3.94 1.86 3.62 5.47 2.58
Day 3 mean 59.61 28.70 41.06 41.61 36.62
SD 21.22 6.28 8.22 6.59 7.42
Day 6 mean 293.32 58.05 83.31 72.16 68.32
SD 40.27 5.25 15.41 12.28 13.25
Day 10 mean 324.62 75.65 84.67 85.07 81.83
SD 32.17 14.95 8.31 16.35 10.49
Day 14 mean 360.71 80.08 103.00 92.62 95.29
SD 45.09 6.45 16.51 16.73 7.74
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MTX at a concentration of 1nM compared to 0.1nM
MTX (p≤ 0.001) (Figure 6).
Discussion
The aim of this study was to investigate, whether low dose
MTX causes changes in osteogenic differentiation, prolif-
eration and metabolism. Other authors previously investi-
gated the effect of low dose MTX on mouse osteogenic cell
line (MCT3-E1), human osteoblastic osteosarcoma cellsFigure 4 Results of Cell Counting.(UMR-106), human bone marrow stromal cells (BMSC)
or human bone derived cells (HBDC) with controversial
results [19,20]. Uehara et al. suggested that MTX inhibits
the differentiation of early osteoblastic cells, without effect-
ing proliferation of late-stage osteoblasts. In spite of this,
Minaur and colleges observed that concentrations of
≥10nM MTX inhibits the proliferation of primitive mar-
row stromal cells but did not alter their maturation. More-
over, they found no influence of MTX on cells of the
osteoblast linage, neither in differentiation nor in
Figure 5 Results of the MTT – assay.
Annussek et al. Head & Face Medicine 2012, 8:26 Page 7 of 9
http://www.head-face-med.com/content/8/1/26proliferation. In fact we firstly described a strong and dose
independent reduction of middle-stage differentiated, bo-
vine osteoblast`s cell proliferation by a variety of experi-
mental methods at therapeutically relevant MTX
concentrations of 1-1000nM found in cortical bone by
Bologna et al. [18]. In our study, we could clearly demon-
strate that even lower concentrations of MTX within
common therapeutical margins led to significant decrease
of osteoblast’s proliferation and metabolism. The apparent
discrepancy to earlier studies could be explained by meth-
odological diversity, implicating the MTT-assay being
more sensitive compared to electronic particle counter.
Moreover time of incubation seems to be an important
variety. Even if we could observe differences between
MTX concentrations of 1-1000nM, there was no straight
proportionality, so that a dose independent effect is as-
sumable within these ranges of MTX-concentration. AlsoTable 3 Results of MTT-assay at day 7 to determine the
critical MTX-concentration
MTX concentration [nM] MTT extinction
mean SD 95% Confidence interval
0 (Control) 0.687 0.033 0.673 – 0.701
0,0001 0.684 0.046 0.655 – 0.713
0,001 0.690 0.028 0.673 – 0.708
0,01 0.689 0.029 0.671 – 0.707
0,1 0.424 0.044 0.396 – 0.453
1 0.213 0.031 0.193 – 0.233a low concentration of 0.1nM MTX showed still signifi-
cant inhibitory effects on osteoblast´s, proliferation and
mitochondrial metabolism. More over the incidence of
interaction appeared rapidly. We determined a critical
value of 0.01nM MTX and below in which no more
impairments of osteoblast´s, proliferation and viability
could be detected. These concentrations are more than
hundredfold lower than levels measured in RA patients
receiving MTX in therapeutical dosages and more than a
thousand times lower than critical inhibitory values of
MTX concentration described before [21]. In our point of
view, this is also a proof that the methods used in this
study, especially the MTT-assay, feature even detection of
effects on cells at very low pharmacological concentra-
tions of administered agents. We agree with published
data from Scheven et al., that osteogenic differentiation
and synthesis of proteins of the primary cells are not
affected, as shown by immunostaining. In fact primary
cells are able to react sensitively to minor alterations of
their surrounding [22]. This is why in our opinion the use
of primary cells as drug testing system seems to be the
most advisable to detect potent adverse reactions
concerning bone in general and also of the bone in the
cranio-maxillofacial region in particular. Certainly, bone
metabolism is also dependent on osteoclasts, but evi-
denced based data are already missing to assess their
behaviour while MTX incubation.
We pointed out the possible inhibitory effect of MTX
on osteoblast`s proliferation and metabolism. This could
Figure 6 Determination of critical inhibitory MTX – concentration. Results of the MTT – assay at day 7.
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bone development, bone regeneration and bone healing.
Of special interest in the oral and maxillofacial field are
possible negative effects of MTX on bone healing after
tooth extractions, bony resections, and augmentations in
reconstructive surgery. However, evidenced based recom-
mendations for perioperative use of MTX are barley avail-
able [23]. Concerning oral rehabilitation of RA patients
with the help of dental implants, it has to be considered
that reduced proliferation of bone cells like osteoblasts
maybe associated with reduced osseointegration of dental
implants. Controversially discussed clinical questions, e.g.
if MTX means a contraindication for dental implantations
or if special protocols with regard to prolonged osseointe-
gration time have to be developed, have to be left un-
answered because of lacking experimental and clinical
evidence. Nevertheless, more in vitro and in vivo as well
as clinical data have to be collected to give a precise ap-
praisal of surgical outcome or failure concerning the oral
and maxillofacial region.
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